Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 5, 2016, Pages 1414-1423.e9

  de Maat, Steven ^a   Björkqvist, Jenny ^b,c   Suffritti, Chiara ^d   Wiesenekker, Chantal P ^a   Nagtegaal, Willem ^a   Koekman, Arnold ^a   van Dooremalen, Sanne ^a   Pasterkamp, Gerard ^a   de Groot, Philip G ^a   Cicardi, Marco ^d   Renné, Thomas ^b,c   Maas, Coen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Angioedema; bradykinin; C1 esterase inhibitor; Factor XII; kininogen; plasma kallikrein; plasmin

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; LYSINE; PLASMIN; PLASMINOGEN; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT;

ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MUTATION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; GENETICS; METABOLISM; PREGNANCY;

AMINOCAPROIC ACID; ANGIOEDEMAS, HEREDITARY; ANTIFIBRINOLYTIC AGENTS; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; FACTOR XII; FEMALE; FIBRINOLYSIN; HUMANS; MUTATION; PREGNANCY;

EID: 84964608755     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.02.021     Document Type: Article

References (53)

1. 1 Bygum, A., Aygören-Pürsün, E., Beusterien, K., Hautamaki, E., Sisic, Z., Wait, S., et al. Burden of illness in hereditary angioedema: a conceptual model. Acta Derm Venereol 95 (2015), 706–710.
2. 2 Cicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J.A., Bork, K., et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69 (2014), 602–616.
3. 3 Nussberger, J., Cugno, M., Cicardi, M., Bradykinin-mediated angioedema. N Engl J Med 347 (2002), 621–622.
4. 4 Kaplan, A.P., Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 126 (2010), 918–925.
5. 5 Bork, K., Barnstedt, S.E., Koch, P., Traupe, H., Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356 (2000), 213–217.
6. 6 Cichon, S., Martin, L., Hennies, H.C., Müller, F., Van Driessche, K., Karpushova, A., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79 (2006), 1098–1104.
7. 7 Dewald, G., Bork, K., Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343 (2006), 1286–1289.
8. 8 Bork, K., Wulff, K., Meinke, P., Wagner, N., Hardt, J., Witzke, G., A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 141 (2011), 31–35.
9. 9 Nilsson, T., Bäck, O., Elevated plasmin-alpha 2-antiplasmin complex levels in hereditary angioedema: evidence for the in vivo efficiency of the intrinsic fibrinolytic system. Thromb Res 40 (1985), 817–821.
10. 10 Nielsen, E.W., Johansen, H.T., Høgåsen, K., Wuillemin, W., Hack, C.E., Mollnes, T.E., Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 44 (1996), 185–192.
11. 11 Reshef, A., Zanichelli, A., Longhurst, H., Relan, A., Hack, C.E., Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy 70 (2015), 506–513.
12. 12 Csuka, D., Veszeli, N., Imreh, É., Zotter, Z., Skopál, J., Prohászka, Z., et al. Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis, 10, 2015, 132.
13. 13 Joseph, K., Tholanikunnel, B.G., Wolf, B., Bork, K., Kaplan, A.P., Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol, 2015 [Epub ahead of print].
14. 14 Hill, M.D., Lye, T., Moss, H., Barber, P.A., Demchuk, A.M., Newcommon, N.J., et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 60 (2003), 1525–1527.
15. 15 Werner, R., Keller, M., Woehrle, J.C., Facial angioedema and stroke. Cerebrovasc Dis 38 (2014), 101–106.
16. 16 Correia, A.S., Matias, G., Calado, S., Lourenço, A., Viana-Baptista, M., Orolingual angiodema associated with alteplase treatment of acute stroke: a reappraisal. J Stroke Cerebrovasc Dis 24 (2015), 31–40.
17. 17 Ewald, G.A., Eisenberg, P.R., Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 91 (1995), 28–36.
18. 18 Firinu, D., Bafunno, V., Vecchione, G., Barca, M.P., Manconi, P.E., Santacroce, R., et al. Characterization of patients with angioedema without wheals: the importance of F12 gene screening. Clin Immunol 157 (2015), 239–248.
19. 19 Mansi, M., Zanichelli, A., Coerezza, A., Suffritti, C., Wu, M.A., Vacchini, R., et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med 277 (2015), 585–593.
20. 20 Wintenberger, C., Boccon-Gibod, I., Launay, D., Fain, O., Kanny, G., Jeandel, P., et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 178 (2014), 112–117.
21. 21 Benson, D.A., Karsch-Mizrachi, I., Lipman, D.J., Ostell, J., Wheeler, D.L., GenBank. Nucleic Acids Res 33:Database issue (2005), D34–D38.
22. 22 Wilkins, M.R., Gasteiger, E., Bairoch, A., Sanchez, J.C., Williams, K.L., Appel, R.D., et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112 (1999), 531–552.
23. 23 Bork, K., Wulff, K., Hardt, J., Witzke, G., Lohse, P., Characterization of a partial exon 9/intron 9 deletion in the coagulation factor XII gene (F12) detected in two Turkish families with hereditary angioedema and normal C1 inhibitor. Haemophilia 20 (2014), e372–e375.
24. 24 Björkqvist, J., de Maat, S., Lewandrowski, U., Di Gennaro, A., Oschatz, C., Schönig, K., et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 125 (2015), 3132–3146.
25. 25 Hovinga, J.K., Schaller, J., Stricker, H., Wuillemin, W.A., Furlan, M., Lämmle, B., Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353–>Pro leading to loss of a kallikrein cleavage site. Blood 84 (1994), 1173–1181.
26. 26 Revak, S.D., Cochrane, C.G., Bouma, B.N., Griffin, J.H., Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 147 (1978), 719–729.
27. 27 Citarella, F., Wuillemin, W.A., Lubbers, Y.T., Hack, C.E., Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 99 (1997), 197–205.
28. 28 Asmis, L.M., Sulzer, I., Furlan, M., Lämmle, B., Prekallikrein deficiency: the characteristic normalization of the severely prolonged activated partial thromboplastin time following increased preincubation time is due to autoactivation of factor XII. Thromb Res 105 (2002), 463–470.
29. 29 Kaplan, A.P., Austen, K.F., A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133 (1971), 696–712.
30. 30 Bork, K., Wulff, K., Witzke, G., Stanger, C., Lohse, P., Hardt, J., Antihistamine-resistant angioedema in women with negative family history: estrogens and F12 gene mutations. Am J Med 126 (2013), 1142.e9–1142.e14.
31. 31 Tersteeg, C., de Maat, S., De Meyer, S.F., Smeets, M.W.J., Barendrecht, A.D., Roest, M., et al. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 129 (2014), 1320–1331.
32. 32 Bouma, B., Maas, C., Hazenberg, B.P.C., Lokhorst, H.M., Gebbink, M.F.B.G., Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost 5 (2007), 1139–1142.
33. 33 Maas, C., Govers-Riemslag, J.W.P., Bouma, B., Schiks, B., Hazenberg, B.P.C., Lokhorst, H.M., et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118 (2008), 3208–3218.
34. 34 Nuijens, J.H., Huijbregts, C.C., Eerenberg-Belmer, A.J., Abbink, J.J., Strack van Schijndel, R.J., Felt-Bersma, R.J., et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 72 (1988), 1841–1848.
35. 35 Defendi, F., Charignon, D., Ghannam, A., Baroso, R., Csopaki, F., Allegret-Cadet, M., et al. Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One, 8, 2013, e70140.
36. 36 Dors, D.M., Nuijens, J.H., Huijbregts, C.C., Hack, C.E., A novel sensitive assay for functional factor XII based on the generation of kallikrein-C1-inhibitor complexes in factor XII-deficient plasma by glass-bound factor XII. Thromb Haemost 67 (1992), 644–648.
37. 37 Nussberger, J., Cugno, M., Cicardi, M., Agostoni, A., Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104 (1999), 1321–1322.
38. 38 de Maat, S., de Groot, P., Maas, C., Contact system activation on endothelial cells. Semin Thromb Hemost 40 (2014), 887–894.
39. 39 Kiss, N., Barabás, E., Várnai, K., Halász, A., Varga, L.Á., Prohászka, Z., et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 149 (2013), 142–145.
40. 40 Gelincik, A., Demir, S., Olgaç, M., Karaman, V., Toksoy, G., Çolakoğlu, B., et al. Idiopathic angioedema with F12 mutation: is it a new entity?. Ann. Allergy Asthma Immunol 114 (2015), 154–156.
41. 41 Kleniewski, J., Blankenship, D.T., Cardin, A.D., Donaldson, V., Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 120 (1992), 129–139.
42. 42 van der Linden, P.W., Hack, C.E., Struyvenberg, A., Roem, D., Brouwer, M.C., de Boer, J.P., et al. Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock. Blood 82 (1993), 1740–1748.
43. 43 van der Linden, P.W., Hack, C.E., Eerenberg, A.J., Struyvenberg, A., van der Zwan, J.K., Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock. Blood 82 (1993), 1732–1739.
44. 44 Li, J., Ny, A., Leonardsson, G., Nandakumar, K.S., Holmdahl, R., Ny, T., The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 166 (2005), 783–792.
45. 45 Sainz, I.M., Uknis, A.B., Isordia-Salas, I., Cadena DeLa, R.A., Pixley, R.A., Colman, R.W., Interactions between bradykinin (BK) and cell adhesion molecule (CAM) expression in peptidoglycan-polysaccharide (PG-PS)-induced arthritis. FASEB J 18 (2004), 887–889.
46. 46 McLaren, M., Alkaabi, J., Connacher, M., Belch, J.J.F., Valenete, E., Activated factor XII in rheumatoid arthritis. Rheumatol Int 22 (2002), 182–184.
47. UniProt Consortium. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res 2014;42(Database issue):D191-8.
48. Wilkins, M.R., Gasteiger, E., Bairoch, A., Sanchez, J.C., Williams, K.L., Appel, R.D., et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112 (1999), 531–552.
49. Steentoft, C., Vakhrushev, S.Y., Joshi, H.J., Kong, Y., Vester-Christensen, M.B., Schjoldager, K.T.-B.G., et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J 32 (2013), 1478–1488.
50. de Maat, S., van Dooremalen, S., de Groot, P.G., Maas, C., A nanobody-based method for tracking factor XII activation in plasma. Thromb Haemost 110 (2013), 458–468.
51. Roovers, R.C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A.J., Revets, H., et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 56 (2007), 303–317.
52. Studier, F.W., Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41 (2005), 207–234.
53. Roovers, R.C., Henderikx, P., Helfrich, W., van der Linden, E., Reurs, A., de Bruïne, A.P., et al. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br J Cancer 78 (1998), 1407–1416.